UBTECH launches UWORLD U1; BofA reiterates Buy and slightly raises target price

Overview

This report focuses on the business and valuation impact following UBTECH's (9880.HK) launch of the UWORLD U1 full-size bionic humanoid robot. BofA believes that order intake and delivery commencement for the U1 series in companion and service scenarios will increase the company's expected humanoid robot shipments in 2026-2028E and support revenue growth and gross margin expansion, and therefore reiterates its Buy rating.

Core views

The core view is that the UWORLD U1 series opens incremental room in consumer-grade and service-oriented humanoid robots, with 13.4k on-hand orders providing early demand validation; as deliveries begin in 2H26 and overseas expansion progresses in 2027, the company's humanoid robot revenue is expected to grow rapidly. The report also expects UBTECH's net loss to continue narrowing in 2026, with profitability achieved in 2027, and slightly raises the target price to HKD162.

Analysis framework

Starting from new product specifications, orders, pricing, delivery pace, and comparisons with peer robot models, the report raises UBTECH's 2026-2028E revenue and EPS forecasts; valuation adopts the average of DCF and P/S methods, and derives the target price in combination with the target P/S multiple, WACC, perpetual growth rate, and long-term mature market assumptions.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow valuation

  The report calculates a DCF fair value of HKD139.1 based on a 12.1% WACC and a 3.0% perpetual free cash flow growth rate; due to more conservative long-term growth assumptions after 2030 as the market matures, the DCF valuation is lower than before.

• Valuation methodsP/S

  Price-to-sales valuation

  The report applies a target P/S multiple of 10x to 2027E sales, arriving at a P/S fair value of HKD184.7; the target multiple is in line with the average P/S over the past year.

• Research frameworkiQmethod5

  BofA standard financial metrics framework

  iQmethod5 is used to standardize definitions of business performance, earnings quality, and valuation metrics, including ROE, operating margin, free cash flow, P/E, P/B, EV/Sales, and EV/EBITDA.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 9880.HK / UBTECH

  The covered target in the report; UWORLD U1 is the core catalyst behind this earnings forecast upgrade and target price revision.

  Strengths

  UBTECH is a leading company in China's humanoid robot and intelligent service robot markets, with products covering consumer, education, logistics, service, and humanoid robots; the U1 series has already secured sizable orders and offers selling points such as bionic interaction, an emotional LLM, and high computing power.

  Weaknesses

  The company is still in the loss-narrowing stage and is still expected to post a loss in 2026E; free cash flow remains negative, and the lower DCF valuation reflects more conservative long-term growth in a mature market.

  Comparison

  The report compares the U1 series with humanoid robots launched in recent years by AgiBot, XPeng, 1X Technologies, Unitree, Figure AI, Fourier Intelligence, Tesla, and others, highlighting the U1's positioning and price range for companion and service scenarios.

  Risks

  Key risks include slower-than-expected development of humanoid robots, intensifying competition, shortages of key components and materials, and insufficient access to financial resources.

Key data

• U1 series orders13.4k unitsAs of June 30, 2026, UBTECH disclosed that the U1 series had received 13.4k orders.
• Delivery and overseas expansionDeliveries begin on September 16, 2026; overseas expansion in 2027The report views delivery commencement and overseas expansion as key milestones for subsequent volume ramp-up.
• U1 Pro specifications24 active degrees of freedom, 64 passive degrees of freedom, 33 facial degrees of freedom, 200 TOPS computing powerThe product features eye tracking, sound source localization, electronic skin, and the Resonance-LM emotional LLM.
• U1 series pricingU1 Pro RMB169.8k; U1 Lite RMB119.8k; U1 Ultra RMB990.0k/880.0kU1 Ultra prices correspond to the male/female versions, respectively.
• Revenue forecast revision2026/27/28E raised by 15%/19%/20%The report says the upward revision mainly comes from higher shipment expectations for humanoid robots, especially UWORLD.
• Net profit path2026E net loss RMB209mn; 2027E net profit RMB138mn; 2028E net profit RMB527mnThe report expects the company to turn profitable in 2027.
• Target priceHKD162.00Raised from the previous HKD160, based on the average of DCF and P/S valuations.
• Current share priceHKD102.80Corresponding to implied upside to the target price of about 57.6%.
• Valuation breakdownDCF HKD139.1; P/S HKD184.7The P/S valuation is based on 10x 2027E P/S; DCF assumes 12.1% WACC and 3.0% perpetual growth.

Impact & implications

For investors, the main implication of the report is that UBTECH's investment case is shifting further from pure R&D and concept validation toward validation of order conversion, delivery pace, and the profitability inflection point. If the U1 series is delivered as planned and continues to win orders, revenue growth and gross margin improvement could support valuation; however, if delivery, the supply chain, or the competitive landscape falls short of expectations, the current valuation elasticity based on 2027E sales and long-term growth could also face downside pressure.

Risks

• The development and commercialization of humanoid robot products may be slower than expected.
• Competition in the humanoid robot industry may intensify, potentially compressing pricing, order conversion, and margins.
• Insufficient supply of key components or materials may affect the delivery schedule.
• The company still needs financial resources to support expansion, and financing or cash flow pressure may affect execution.
• The company is still expected to post a loss in 2026E and free cash flow remains negative; the profitability inflection point requires further validation through subsequent deliveries and gross margin improvement.

What to watch

• After September 16, actual delivery volume, delivery pace, and order conversion rate for the U1 series.
• Cancellation rate, customer mix, and payment progress for the 13.4k on-hand orders.
• Channels, certifications, pricing, and demand feedback for the 2027 overseas expansion.
• Delivery of humanoid robot shipment volume, revenue growth, and gross margin in 2026-2028E.
• The impact of new peer product launches and price competition on demand for the U1 series.
• Progress in component supply, working capital usage, and free cash flow improvement.